30th PAGE Meeting

Ljubljana - Slovenia
28 June - 1 July, 2022

View abstracts

Home / 2022 – Ljubljana – Slovenia / Abstracts

← Back to filters

Abstracts (18)

IV-04Vanessa Baier

PBPK model-guided assessment of a liver function test

Thursday 15:00-16:30

IV-05Pavel Balazki

PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i.

Thursday 15:00-16:30

IV-06Sara Bettonte

Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling

Thursday 15:00-16:30

IV-10Letizia Carrara

Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling

Thursday 15:00-16:30

IV-13Marylore Chenel

Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children

Thursday 15:00-16:30

IV-17Yumi Cleary

Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity

Thursday 15:00-16:30

IV-27Laura Fuhr

Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling

Thursday 15:00-16:30

IV-39Helena Loer

Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach

Thursday 15:00-16:30

IV-42Fatima Zahra Marok

Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole

Thursday 15:00-16:30

IV-44Nina Nauwelaerts

Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project

Thursday 15:00-16:30

IV-46Fiona Plait

Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4

Thursday 15:00-16:30

IV-47Alicja Puszkiel

A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis

Thursday 15:00-16:30

IV-48Javier Reig-López

A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites

Thursday 15:00-16:30

IV-51Ayatallah Saleh

Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach

Thursday 15:00-16:30

IV-52Morwarid Shahhossini

Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock

Thursday 15:00-16:30

IV-53Yesong Shin

Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean

Thursday 15:00-16:30

IV-55Erik Sjögren

A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework

Thursday 15:00-16:30

IV-61Eunsol Yang

Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole

Thursday 15:00-16:30